South Korean regenerative medicine firm L&C Bio is expanding the application of its ECM-based skin booster Re2O (리투오) into the hair loss treatment market, shifting focus from hair growth stimulation to scalp tissue regeneration. The company announced on March 17 that Re2O is gaining attention as a novel regenerative alternative, particularly as Korean health insurance discussions increasingly recognize hair loss as a disease rather than a cosmetic issue.
Clinical spotlight at Hair Loss Academy
On March 13, the Korean Society of Dermatology and Obesity & Plastic Surgery hosted the 'Hair Loss Practical Academy,' where Dr. Kim Ji-hyun of Yonsei Mida Clinic presented the latest insights on ECM-based regenerative therapy and real-world clinical applications. The event included a workshop demonstrating Re2O scalp treatment using L&C Bio's i-Jet injection platform. Attending clinicians showed strong interest in the procedure's convenience and clinical feasibility.
Technology differentiation: ECM microenvironment restoration
Re2O is an ECM-based regenerative medical material derived from micronized human acellular dermal matrix (hADM). Unlike conventional hair loss therapies that focus on stimulating hair follicle cell growth or modulating androgen action, Re2O targets the restoration of the tissue microenvironment surrounding hair follicles. According to academic sources, hair loss involves follicle stem cell dysfunction, ECM structure loss, and fibrosis. The scalp ECM—composed of collagen, elastin, and proteoglycans—supports follicles and stores growth factors. Aging, inflammation, and androgen exposure damage this ECM, creating an unfavorable environment for hair growth.
Expert perspective: Restoring follicle habitat
Dr. Kim emphasized during her lecture: "The ultimate goal of hair loss treatment is not simply to thicken hair but to restore the environment in which follicles can remain healthy. ECM regeneration can be a new therapeutic approach to normalize the tissue around follicles." By supplying human dermis-derived ECM components, Re2O induces ECM reconstruction in damaged scalp dermis and acts as a biological scaffold for tissue regeneration. This marks a shift from cell-centric regenerative medicine to ECM-driven platform strategies, expanding from skin, wound, and reconstruction fields into hair loss.
Regulatory and channel signals
L&C Bio's Re2O is already established in skin regeneration, and the company is now targeting the hair loss market. The Korean Society of Dermatology and Obesity & Plastic Surgery plans to hold a symposium at its autumn academic conference presenting clinical data on Re2O for hair loss and its tissue regeneration mechanism. This signals growing institutional interest and potential for broader clinical adoption.
What buyers should watch
For overseas distributors and clinic buyers, Re2O represents a differentiated ECM-based injectable platform that addresses the scalp microenvironment—a gap in current oral and topical hair loss treatments. The product's compatibility with the i-Jet injection system may offer procedural efficiency. L&C Bio's expanding global footprint, including recent approvals in Mongolia and production scale-up, suggests increasing supply capacity. Importers should monitor upcoming clinical data from the Korean society symposium and evaluate regulatory pathways for their markets.
Source: Read the original report | Published: June 17, 2026